SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-23-008621
Filing Date
2023-03-30
Accepted
2023-03-30 16:10:15
Documents
15
Period of Report
2023-03-30
Items
Item 2.02: Results of Operations and Financial Condition
Item 4.02: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K acrx20230330_8k.htm   iXBRL 8-K 28825
2 EXHIBIT 99.1 ex_495013.htm EX-99.1 166712
7 logo01.jpg GRAPHIC 9001
  Complete submission text file 0001437749-23-008621.txt   358679

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA acrx-20230330.xsd EX-101.SCH 3601
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE acrx-20230330_def.xml EX-101.DEF 11532
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE acrx-20230330_lab.xml EX-101.LAB 15414
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE acrx-20230330_pre.xml EX-101.PRE 11688
9 EXTRACTED XBRL INSTANCE DOCUMENT acrx20230330_8k_htm.xml XML 2574
Mailing Address 25821 INDUSTRIAL BOULEVARD SUITE 400 HAYWARD CA 94545
Business Address 25821 INDUSTRIAL BOULEVARD SUITE 400 HAYWARD CA 94545 650-216-3500
ACELRX PHARMACEUTICALS INC (Filer) CIK: 0001427925 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35068 | Film No.: 23780777
SIC: 2834 Pharmaceutical Preparations